Literature DB >> 6220094

Immunochemical characterization of the mucoid exopolysaccharide of Pseudomonas aeruginosa.

G B Pier, W J Matthews, D D Eardley.   

Abstract

Alginic acid-like mucoid exopolysaccharide was isolated from three strains of Pseudomonas aeruginosa obtained from the sputa of patients with cystic fibrosis. Purified mucoid antigens were greater than 99% uronic acid. With a hemagglutination assay, antibody responses to the mucoid exopolysaccharide were documented after immunization of rabbits with either whole mucoid organisms or purified mucoid exopolysaccharide. The mucoid antigen from one strain (no. 2192) was composed predominantly of a single serologic epitope shared among 40 alginate exopolysaccharides from different clinical isolates. The mucoid exopolysaccharide from the other two strains (nos. 1 and 258) had a serotype-specific determinant in addition to the common epitope. Analyses of antibody in sera from normal adults, children, and patients with cystic fibrosis culture-positive and culture-negative for mucoid P. aeruginosa showed a highly significant (P less than 0.001) association between increased hemagglutination titers and positive cultures for mucoid P. aeruginosa.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6220094     DOI: 10.1093/infdis/147.3.494

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  50 in total

1.  Polyclonal and monoclonal antibody therapy for experimental Pseudomonas aeruginosa pneumonia.

Authors:  J E Pennington; G J Small; M E Lostrom; G B Pier
Journal:  Infect Immun       Date:  1986-10       Impact factor: 3.441

2.  AlgR, a response regulator controlling mucoidy in Pseudomonas aeruginosa, binds to the FUS sites of the algD promoter located unusually far upstream from the mRNA start site.

Authors:  C D Mohr; N S Hibler; V Deretic
Journal:  J Bacteriol       Date:  1991-08       Impact factor: 3.490

3.  Pseudomonas aeruginosa immunotherapy.

Authors:  J E Pennington
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-06       Impact factor: 3.267

4.  Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype.

Authors:  R B Parad; C J Gerard; D Zurakowski; D P Nichols; G B Pier
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

5.  Alginate production by plant-pathogenic pseudomonads.

Authors:  W F Fett; S F Osman; M L Fishman; T S Siebles
Journal:  Appl Environ Microbiol       Date:  1986-09       Impact factor: 4.792

6.  Aeration selects for mucoid phenotype of Pseudomonas aeruginosa.

Authors:  D P Krieg; J A Bass; S J Mattingly
Journal:  J Clin Microbiol       Date:  1986-12       Impact factor: 5.948

Review 7.  Recent developments for Pseudomonas vaccines.

Authors:  Anurag Sharma; Anja Krause; Stefan Worgall
Journal:  Hum Vaccin       Date:  2011-10-01

8.  Dynamics of Pseudomonas aeruginosa genome evolution.

Authors:  Kalai Mathee; Giri Narasimhan; Camilo Valdes; Xiaoyun Qiu; Jody M Matewish; Michael Koehrsen; Antonis Rokas; Chandri N Yandava; Reinhard Engels; Erliang Zeng; Raquel Olavarietta; Melissa Doud; Roger S Smith; Philip Montgomery; Jared R White; Paul A Godfrey; Chinnappa Kodira; Bruce Birren; James E Galagan; Stephen Lory
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

9.  Multiple promoters and induction by heat shock of the gene encoding the alternative sigma factor AlgU (sigma E) which controls mucoidy in cystic fibrosis isolates of Pseudomonas aeruginosa.

Authors:  M J Schurr; H Yu; J C Boucher; N S Hibler; V Deretic
Journal:  J Bacteriol       Date:  1995-10       Impact factor: 3.490

Review 10.  Comparative transcriptome analyses of Pseudomonas aeruginosa.

Authors:  Deepak Balasubramanian; Kalai Mathee
Journal:  Hum Genomics       Date:  2009-07       Impact factor: 4.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.